Together, these results indicated the potential synergy of the BBR and gefinitib combination on the growth, migration, invasion inhibition and enhanced cell death in NSCLC including the EGFR‐TKI–resistant lung cancer cells. This evidence concerns the gene EGFR and lung carcinoma.